Recursion Pharmaceuticals reported a revenue increase in Q1 2023, driven by progress in the Roche-Genentech collaboration. The company also advanced its clinical trials and made strategic acquisitions of Cyclica and Valence to bolster its digital chemistry and generative AI capabilities. However, the company experienced increased research and development expenses and general and administrative expenses, leading to a higher net loss compared to the same period last year.